This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Bacil Pharma Q2 results: Revenue falls 83 percent YoY, cash flow turns negative
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited results for Q2 and H1 ending Sept 30, 2026. Revenue fell sharply to 18.09 lakhs in H1 from 105.74 lakhs last year, about 83 percent decline. Standalone profit before tax was 9.89 lakhs on expenses of 8.20 lakhs. Standalone operating cash flow was negative 224.89 lakhs versus positive 171.46 prior year. Statutory auditors issued a clean limited review with no qualifications.
Sharp revenue fall and negative operating cash flow are red flags. Watch the next quarters closely for recovery signs.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.00 Cr | unchanged |
| Operating profit | −₹0.06 Cr | −₹0.04 Cr | loss widened |
| Profit after tax | ₹0.15 Cr | ₹0.01 Cr | +1,008.0% |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.